Yuewei Medical Secures Nearly RMB 100 Million in Series B Funding Within One Year of Two Rounds, Advances Cardiovascular Device Innovation
Yellwin
Cardiac Surgery Implantable Medical Device R&D Provider
Heart Future
Recently,Yellwin("Yellwin")" announced the completionNearly 100 Million Yuan in Series B FinancingThis round of financing was led by EF Capital, with participation from Beishang Capital and Bohai Chuangfu, and Win Capital served as the exclusive financial advisor.
This is Yellwin's second large-scale financing this year, fully demonstrating the capital market's high recognition of the company's development progress.
Through this round of financing, Yellwin will continue to comprehensively strengthen its R&D innovation and market penetration capabilities in cardiovascular surgery and other extended fields, continuously consolidating its leading position.
Yellwin's financing process has been steady and methodical. Since its establishment, the company has completed multiple rounds of financing. The continuous influx of funds fully demonstrates the strong recognition from the capital market of Yellwin's product innovation and clinical value.
# Financing History
2021Year9Month：Angel RoundFinancing
2023Year4Month：Yellwin has also completedCompletedTens of Millions of YuanAWheelFinancing, this round of financing was led byIDGLed by Capital and followed by Yuanhui Chuangyi. This round of financing has provided strong financial support for Yellwin's R&D products, especially for innovative products in the field of coronary heart disease and heart failure, accelerating Yellwin's R&D progress.
2023Year12Month: By Nuoyu Capital, Zhongnan Venture Capital, Qichen Holdings,IDGCapital and Yuanhui Chuangyi jointly invested inNearly 100 million yuanA+WheelFinancing
2025Year4Month：Yellwin Announces Completion of Exclusive Investment by Beijing Medical and Health Industry Investment FundTens of Millions of YuanA++RoundFinancing. The funds will be mainly used for further research and development of core products such as the new generation of cardiac stabilizers, vascular anastomosis quality control systems, and pulsatile left ventricular assist systems, as well as to accelerate the market promotion of already approved products like cardiac stabilizers.
# Product Introduction
Yellwin focuses on the research and development of innovative medical devices in the field of cardiovascular surgery and has achieved remarkable results in multiple niche areas. The company's core products under development includeNew Generation Heart Stabilizer, Vascular Anastomosis Quality Control System, Pulsatile Left Ventricular Assist System, Coronary Heart Disease Scoring SystemThese products not only fill the gap in the Chinese market but also possess strong competitiveness internationally.
1. New Generation Heart Stabilizer
Yellwin's new generation of heart stabilizers adopts a modular design, capable of meeting the needs of different surgical scenarios. Particularly in response to the minimally invasive trend in coronary surgery, it has revolutionized the design concept of traditional heart stabilizers, fundamentally assisting physicians in achieving complete revascularization under direct-view minimally invasive conditions.
This fixator can be widely used in various coronary artery bypass surgeries, especially offering significant advantages in complex cases and minimally invasive procedures.
2. Pulsatile Left Ventricular Assist System
Yellwin's self-developed pulsatile percutaneous left ventricular assist device (PVAD) is developed based on the clinical pain points in severe cardiac surgery treatment, while also meeting the diagnostic and treatment needs of patients with cardiogenic shock in cardiology scenarios.
YellwinPVADThe product not only hasIABPLow product cost, high safety, no needDSAAuxiliary and other advantages also make up forIABP、PulseCathTraditional pulsatingPVADThe problem of insufficient flow in the product exists, and the product strives to...IMPELLARepresentative of the Plug Flow TypePVADThe products complement each other, providing Chinese cardiovascular physicians with a powerful, domestically innovated tool to address high-risk patients.
3. Vascular Anastomosis Quality Control System
This system solves a major problem in coronary artery bypass surgery.——Control of Anastomosis Quality. Through an intelligent quality control system, Yellwin's vascular anastomosis quality control system can monitor data such as pressure and flow in real time during the anastomosis process, ensuring that each anastomosis meets optimal physiological requirements.
The system plays an important role in improving surgical accuracy and reducing postoperative complications. While surpassing foreign competitors in key metrics, the vascular anastomosis quality control system significantly lowers end-user prices. The product’s market launch will effectively address the insufficient quality control rate in China’s coronary artery surgery (the use of device quality control in coronary artery surgery has been...2010It was written into the guidelines years ago, but currently, the usage rate of quality control instruments in China is only20%）。
4. Coronary Heart Disease Scoring System
Yellwin's Coronary Heart Disease Scoring System, based on artificial intelligence and big data technology, enables precise condition assessment for patients with coronary heart disease. The system provides crucial support for preoperative risk evaluation, intraoperative surgical planning, and postoperative prognosis assessment, allowing doctors to formulate personalized treatment plans with greater accuracy.
Recently, the Ministry of Industry and Information Technology and the Department of Comprehensive Planning and Finance of the National Medical Products Administration jointly announced2025YearPersonWorkWisdomCanMedTherapyDeviceDeviceCreateNewRenMissionRevealListHangHandsomeAdmissionPerimeterSinglePositionNameSingle，YellwinYellwinMedTherapyWith its“PersonWorkWisdomCanCrownStatusMovePulseMadeShadowShadowLikeEvaluationPriceSystemSystem”ItemEyeSuccessfully Shortlisted。
Internationally,The SYNTAX score system is the "gold standard" for selecting revascularization strategies in patients with coronary artery disease. However, the current multi-physician manual scoring model has significant drawbacks, including heavy reliance on physician experience, time consumption, and suboptimal accuracy.YellwinYellwinMedicalTherapyCreateNewResearchIssueThe“PersonWorkWisdomCanCrownStatusMovePulseManufactureShadowShadowLikeEvaluationPriceSystemSystem”，YesAllBallFirstPaymentRealityNowChinaFromMoveAI-SYNTAXEvaluationPriceEffectCanTheSoftItem。The system is based on internationally leadingBuilt from a DSA imaging full coronary artery analysis model, it enables real-time and precise evaluation, outputting scoring results in a highly objective, efficient, and accurate manner.
ThisOneCreateNewAchieveFruitPushMoveCompletedSpreadSystemCrownStatusMovePulseShadowLike“GoldMarkAccurate”ToNumberCharacterChemicalAndSystemOneTrustCeaseMarkAccurateHuaStrideIn，Precisely meets the hospital's urgent need for efficient and accurate auxiliary diagnostic products, filling the current market gap.
5. Minimally Invasive Great Saphenous Vein Harvesting System
With the development of minimally invasive surgical techniques, the minimally invasive great saphenous vein harvesting system has become an essential tool in coronary artery bypass surgery. Yellwin's system minimizes trauma, reduces postoperative recovery time for patients, and ensures the quality of vein harvesting, providing more ideal vascular grafts for coronary artery bypass surgery.
# Company Introduction
YellwinFounded inIn September 2021, headquartered in Beijing. Based on the founding team's extensive clinical experience, the company identifies clinical needs and develops multiple globally first, China-first, or market-gap-filling medical devices, while also considering the current state of relevant fields.
Currently Self-developedCoronary Surgery, Critical Care, and Extracorporeal CirculationTwo major product lines, including nearly 10 products, among whichUltrasonic Vascular Flow Measurement System, Pulsatile Left Ventricular Assist System, Dual-Lumen Jugular Catheter...are all products that are first-of-their-kind in China.
Professor Yang Yu, Chief Scientist of YellwinOnceProposed:"All projects of Yellwin since its establishment have three characteristics:
High Degree of Clinical Acceptance——All core projects of the company require no market education, as they are all essential medical devices in the diagnosis and treatment process. Most of them are highly recommended by guidelines and must be used, which gives us a certain advantage in market promotion.
Blue Ocean Competitiveness——Most of the company's core projects lack effective competitors in China, and even if there are competitors, their market penetration has not formed a barrier, which brings opportunities for the company’s future development.
Technical Originality——Yellwin always regards technological innovation as its core competitiveness. Several core projects are global firsts. Even in the presence of competing products, the company has carried out technical upgrades or iterations on their basis, building competitive barriers from multiple aspects such as core technology and production processes.”
GCC2025
Full Disease Solutions for Cardiovascular Devices
Statement
Content Declaration:"Heart of the Future" tracks global medical technology advancements, aiming to deliver technical and industry knowledge. All content is for professional exchange and academic discussion only, and does not constitute medical advice or commercial promotion. Information about companies, products, and registrations mentioned in the text is sourced from publicly available materials or verified channels. If there are any errors or omissions, please contact us for corrections. Email: jacky@suribot.com
Copyright Statement:The original article "Heart Future" is copyrighted by Beijing Siyu Bot Technology Co., Ltd. Without authorization, it is prohibited to reproduce, excerpt, or mirror the content on other websites, official accounts, or commercial platforms. For reprinting, please contact the backstage to obtain authorization. This platform reserves the right to pursue legal responsibilities for unauthorized full-text reproduction, rewriting, or paraphrasing.
